Catalog Advanced Search

Search by Category
Search by Format
Sort By
Search by Favorites
Search by Keyword
Search by Category
Search by Format
Search by Speakers
Credits Offered
Search in Packages
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Favorites
Search by Keyword
Sort By
  • Contains 1 Component(s) Includes a Live In-Person Event on 07/26/2027 at 8:00 AM (EDT)

    Course will be held in Gaithersburg, Maryland, from July 26–30, 2027. More information about the schedule and registration will be available soon.

    This annual Advanced Comprehensive Toxicology Course provides basic training in general toxicology. Participants will obtain an overall understanding of the principles of toxicology and nonclinical safety evaluation with a focus on pharmaceutical development. By popular demand, the course will include discussion of regulatory case studies and hands-on analyses of nonclinical data. The course is intended to benefit individuals working with small and large molecules from biotechnology and pharmaceutical companies, CROs, and regulatory agencies, or individuals interested in or currently practicing toxicology.

    The Advanced Comprehensive Toxicology Course will be held in person in Gaithersburg, Maryland, from July 26–30, 2027. More information about the schedule and registration will be available soon.

    The Advanced Comprehensive Toxicology  course is only being offered as an in-person format. Virtual or hybrid participation is not an option.

    • You must log in to register
      • Early bird pricing available!
      • Nonmember - $2,100
      • Full Member - $1,800
      • Associate Member - $1,800
      • Emeritus Member - $1,800
      • Government Associate Member - $1,800
      • Government Full Member - $1,800
      • Postdoctoral Researcher/Transitional Member - $995
      • Student Member - $995
      • Regular Price after 05/25/2027 11:59 PM
      • Nonmember - $2,200
      • Full Member - $1,900
      • Associate Member - $1,900
      • Emeritus Member - $1,900
      • Government Associate Member - $1,900
      • Government Full Member - $1,900
      • Postdoctoral Researcher/Transitional Member - $1,095
      • Student Member - $1,095
    • More Information
  • Contains 1 Component(s) Includes a Live In-Person Event on 06/14/2027 at 8:00 AM (EDT)

    Course will be held in Gaithersburg, Maryland, from June 14–16, 2027. More information about the schedule and registration will be available soon.

    This ACT course offers an in-depth exploration of regulatory considerations and the toxicologic evaluation and development of protein biologics, modified protein biologics, and specialized biologics, including cell and gene therapies, and oncolytic viruses. Participants gain a thorough understanding of the key principles and methodologies employed in the nonclinical safety assessment of these advanced therapeutic modalities. The curriculum covers a wide range of studies essential for advancing biotherapeutic drug candidates through all stages of drug development from candidate selection to marketing authorization. Topics include general toxicity studies and a variety of specialized studies, such as off-target assessment, safety pharmacology, carcinogenicity, and reproductive and developmental toxicity studies. Additionally, the course provides insight into pharmacokinetic and biodistribution assessments and the potential impact of immunogenicity for various of different therapeutic modalities. Several case studies are used to highlight how specific strategies and issues are approached in different scenarios.

    The ACT course is offered exclusively in person. Virtual or hybrid participation options are not available.

    Monday, June 14, 2027

    Introduction to the Regulation of Biologics, Mary Ellen Cosenza, MEC Regulatory & Toxicology Consulting, LLC 

    Traditional Biologics, Jeanine Bussiere, Amgen Inc. 

    Carcinogenicity Assessment Strategies for Biotherapeutics, John Vahle, Lilly Research Laboratories

    Case Studies and Q&A

    Tuesday, June 15, 2027

    Developmental and Reproductive Toxicity – Assessments and Considerations for Biopharmaceuticals, Wendy Halpern, Retired

    Juvenile Toxicity, Wendy Halpern, Retired

    Modified Molecules and Immunomodulators, Michael Leach, Trident Toxicology, Inc.

    Nontraditional Strategies for Biopharmaceuticals, Michael Leach, Trident Toxicology, Inc.

    Case Studies and Group Discussion, Mary Ellen Cosenza, MEC Regulatory & Toxicology Consulting, LLC, and Jeanine Bussiere, Amgen Inc.

    Wednesday, June 16, 2027

    Toxicology Study Data Interpretation, Mark Milton, Lake Boon Pharmaceutical Consulting, LLC 

    Nonclinical to Clinical Translation, Jay Tibbitts, Gilead Sciences, Inc.  

    Specialized Biologics: Cell Therapies, Hervé Lebrec, HL Toxicology and Preclinical Services

    Preclinical Translation of Gene Therapy, Jessica Lynch, Johnson & Johnson

    Speakers, presentation topics, and/or format are subject to change.

    Detailed course handouts will be provided electronically. Participants must bring a personal computer to view materials. Please ensure to download materials before arriving. Internet will not be provided.

    Times:

    Registration and Check-In: Monday, 7:30 AM–8:00 AM

    Course Presentations: Monday–Wednesday, 8:00 AM–5:00 PM

    Jeanine L. Bussiere, PhD, DABT, ATS

    Jeanine L. Bussiere, PhD, DABT, ATS

    Scientific Executive Director

    Amgen Inc.

    Dr. Jeanine Bussiere is currently the Scientific Executive Director in Translational Safety and Bioanalytical Sciences (TS&BA) at Amgen having moved after the acquisition of Immunex in 2002, where she was the Director of Pharmacology/Toxicology for 3 years. Prior to joining Immunex, Dr. Bussiere was a scientist at Genentech for 8 years. Throughout her career, her work has focused on nonclinical safety supporting the development of biopharmaceuticals across a variety of therapeutic areas. Her additional expertise is in the area of immunotoxicology, and she received the Career Achievement Award from the Biotechnology Specialty Section in 2016. She is a Diplomate of the American Board of Toxicology, a Fellow of the Academy of Toxicological Sciences, and is an active member of the Society of Toxicology, serving on several committees, both elected and appointed. She is a member of the ILSI/HESI Immunotoxicology Technical Committee, and the American College of Toxicology and serves on the editorial board for the Journal of Immunotoxicology. She received her Doctorate from Washington State University and did her postdoctoral work at Temple University, with an emphasis in immunotoxicology. 

    Mary Ellen Cosenza, PhD, MS, DABT, ATS, ERT, RAC

    Mary Ellen Cosenza, PhD, MS, DABT, ATS, ERT, RAC

    Consultant

    MEC Regulatory and Toxicology Consulting

    Dr. Mary Ellen Cosenza is a regulatory consultant with over 30 years of senior leadership experience in the biopharmaceutical industry in the US, Europe, and emerging markets. During her 20-year tenure at Amgen, she led the US Regulatory Department, the International Emerging Markets Regulatory Department, and served as an Executive Director of Global Regulatory Affairs and Safety, focusing on Early Development, Medical Writing, and Inflammation. In addition to her leadership roles in Regulatory Affairs, she also served as the Senior Director of Toxicology at Amgen. Prior to joining Amgen, she served as a Principal Scientist in Toxicology for the Medical Research Division of American Cyanamid Company (now Pfizer).  

    While at Amgen, Dr. Cosenza was responsible for both early- and late-stage development programs resulting in numerous successful IND, CTA, NDA, MAA, and BLA submissions in a wide variety of therapeutic areas and modalities. In addition, she played a key leadership role in preparing teams for global health authority meetings with FDA, EMA, and regional country health authorities, including several FDA Advisory Committee Meetings.

    Dr. Cosenza is recognized as an expert in preclinical biologic drug development and is a founding member of BIO’s BioSafe Preclinical Expert group. She was also a member of an Expert Working Group, operating under the auspices of the International Conference on Harmonization (ICH) for ICH M3(R2). Dr. Cosenza is well-published in the field of biological drug development, has authored several chapters on this topic, and recently co-edited a book on Translation Sciences focused on biologics and innovative products such as cell and gene therapies. She was also a co-editor of a Toxicological Pathology book for non-pathologists.

    Dr. Cosenza is a Diplomat of the American Board of Toxicology, a Fellow of the Academy of Toxicological Sciences (current President), a member of the Society of Toxicology (SOT), Drug Information Association (DIA), and the Regulatory Affairs Professional Society (RAPS), and holds Regulatory Affairs Certification for both the US and EU. Dr. Cosenza is a European Registered Toxicologist (ERT) via the Royal Society of Biology, UK. She is also Treasurer of the International Union of Toxicology (IUTOX). Dr. Cosenza is a member of the American College of Toxicology (ACT), where she has served as a member of the ACT Education Committee, as Councilor, and as Treasurer and then President. She is an adjunct at the University of Southern California, where she teaches a graduate-level course on Food and Drug Toxicology and undergraduate classes on drug development and toxicology.

    Dr. Cosenza received her PhD from St. John’s University, New York, and her MS in Regulatory Science from the University of Southern California, Los Angeles.

    Wendy Halpern, DVM, PhD, DACVP

    Wendy Halpern, DVM, PhD, DACVP

    Retired

    Dr. Wendy Halpern is a Veterinary Pathologist with more than 25 years of experience in the Biopharmaceutical Industry. She earned her DVM and MSc in Veterinary Pathology from the Ohio State University, and then completed a PhD in Biomedical Sciences at the University of New Mexico. She began her career at Human Genome Sciences, where she focused on several monoclonal antibody and fusion protein programs. In 2007, she moved to Genentech, where she spent the next 19 years in positions of increasing responsibility. She retired from Genentech in 2026 as a Senior Fellow in Translational Safety. Over her career, she has supported individual biopharmaceutical programs at all stages from pre-IND through post-market, and across both oncology and non-oncology indications, as well as collaborating across functions and mentoring within Translational Safety. Over the past 15 years, she has focused on nonclinical approaches to better understand and interpret reproductive and developmental toxicity, including dedicated support of pediatrics. She was a BioSafe contributing member for >20 years and served as the BIO representative on the ICH S11 working group from 2015-2020. She was also an active member of the HESI DART Technical Committee for the past 15 years and currently serves as a Councilor on the Executive Committee of the Society of Toxicologic Pathology. Additional professional affiliations include the American College of Veterinary Pathologists, Birth Defects Research and Prevention, and the Safety Pharmacology Society.

    Jessica L. Lynch, PhD, DABT

    Jessica L. Lynch, PhD, DABT

    Distinguished Scientist II

    Johnson & Johnson Innovative Medicine

    Dr. Jessica L. Lynch is a Distinguished Scientist II in Preclinical Sciences & Translational Safety (PSTS) at Johnson & Johnson Innovative Medicine, where she serves as the Specialty Ophthalmology Disease Area Lead and Gene Therapy Modality Lead. She earned her PhD in Neuroscience from the University of Minnesota, is a Diplomate of the American Board of Toxicology, and has more than 15 years of experience advancing innovative therapies from discovery through regulatory submission and approval. In her current role, she provides strategic leadership for ophthalmology and gene therapy programs, guiding nonclinical safety strategies across multiple modalities while partnering closely with therapeutic area leaders, development teams, and regulatory agencies worldwide.  Dr. Lynch serves on multiple external committees in the gene therapy space, including the ASGCT translational science committee, BioSafe CGT working group, and EFPIA gene therapy working group.

    Michael W. Leach, DVM, PhD, DACVP

    Michael W. Leach, DVM, PhD, DACVP

    President

    Trident Toxicology, Inc.

    Dr. Michael W. Leach is the President and Owner of Trident Toxicology, Inc. He is a veterinary pathologist, toxicologist, and drug developer with 3 decades of experience in the biopharmaceutical industry. Dr. Leach received his DVM from Purdue University, his PhD from the University of California, Davis, and is a diplomate of the American College of Veterinary Pathologists. He has worked for Schering-Plough, BASF Bioresearch Corporation, Abbott Bioresearch Center, Wyeth, and Pfizer with involvement in non-GLP early efficacy studies, in GLP-compliant toxicity studies and regulatory interactions supporting all phases of clinical development, in post-marketing activities, and in due diligence and licensing activities. He is an author/co-author on over 80 peer-reviewed papers, invited reviews, and book chapters.

    His responsibilities and roles in various nonclinical drug safety organizations have included acting as a Study Pathologist, as Study Director, as a Therapeutic Area Head/Lead, as the Licensing and Acquisitions Lead, as the Biotherapeutics Safety Lead, and as the departmental representative to the Large Molecule Candidate Quality Guideline Committee; he also founded and led the Biotherapeutics Safety Leadership Team at Pfizer. Dr. Leach has previously served on the BioSafe Preclinical Safety Leadership Committee, the nonclinical safety committee within Biotechnology Innovation Organization (BIO). In 2023, Dr. Leach received the Career Achievement in Biotechnology Award from the Society of Toxicology Biotechnology Specialty Section. Dr. Leach has given over 40 invited presentations. He is a member of the American Veterinary Medical Association, the Society of Toxicology, the American College of Toxicology, the Society of Toxicologic Pathology, and the American College of Veterinary Pathologists. In his spare time, Dr. Leach enjoys scuba diving and underwater photography.

    Hervé Lebrec, PharmD, PhD, DABT

    Hervé Lebrec, PharmD, PhD, DABT

    Consultant

    HL Toxicology and Preclinical Services

    Dr. Hervé Lebrec is the owner of HL Toxicology and Preclinical Services, a company providing consulting services in nonclinical safety assessment/toxicology. He has a proven record of driving strong, science-based strategies for the successful progression of therapeutic candidates at all stages of development. He built strong and diverse teams to successfully develop and conduct nonclinical safety, pharmacokinetics, and immunogenicity assessments of multiple types of products, including small molecules, antibodies, bispecific T cell-engagers, oncolytic viruses, siRNAs, and engineered T cells.

    Before focusing on providing consulting services, he was Vice President, Development Sciences at Sonoma Biotherapeutics, where he oversaw nonclinical safety, immunogenicity, pharmacokinetics, and clinical pharmacology functions. Sonoma Biotherapeutics is developing engineered regulatory T cells for autoimmune diseases.

    Prior to joining Sonoma Bio, he worked in Translational Safety and Bioanalytical Sciences at Amgen Inc., where he most recently served as Executive Director of Translational Safety. He was responsible for leading a team of toxicologists and laboratory-based scientists responsible for the nonclinical safety assessment of multiple types of products (small molecules, antibodies, oncolytic viruses, siRNAs, and engineered T cells) from lead optimization through post-marketing phases. In that function, Hervé also contributed to the preparation of first-in-human oncology clinical study protocols for the proper integration of nonclinical data and translational safety information. Hervé also supported oncology-related business development efforts through fit-for-purpose evaluations. Prior to this, Hervé was a Principal Scientist and Scientific Director in Translational Safety at Amgen, where he served as Project Team Toxicologist.

    Prior to joining Amgen, Dr. Lebrec served at 3M Pharmaceuticals, initially as a Research Specialist and then as Pathology and Toxicology Department Manager, with a focus on the nonclinical safety assessment of small-molecule Toll-like receptor agonists.

    Prior to joining industry, Dr. Lebrec served as Assistant Professor at the University Paris XI. He received his Doctorate in Pharmacy and his PhD in Toxicology from the same university. He is a diplomate of the American Board of Toxicology.

    Dr. Lebrec’s research work and scientific interests have notably focused on immune-related safety issues; he co-chairs the Immunosafety Technical Committee of the nonprofit HESI (Health and Environmental Sciences Institute) and is President of the Biotechnology Specialty Section of the Society of Toxicology. He has contributed to 60 peer-reviewed publications, which can be accessed here: Dr. Hervé Lebrec’s publications.

    Mark N. Milton, PhD

    Mark N. Milton, PhD

    Consultant

    Lake Boon Pharmaceutical Consulting, LLC

    Dr. Mark Milton retired in March 2022 after almost 31 years in the pharmaceutical industry. Over the course of his career, he managed a GLP-compliant bioanalytical laboratory and provided nonclinical and clinical support for LMW compounds, biologics, cell therapies, and gene therapies. He now provides gene therapy and biologics nonclinical and clinical consulting services through Lake Boon Pharmaceutical Consulting, LLC.

    Dr. Milton received a BSc in Biochemistry and Soil Science from UCNW, Bangor, and an MSc in Toxicology and a PhD in Biochemical Toxicology from the University of Surrey, England. Dr. Milton started his career at GD Searle in Skokie, Illinois, before moving to Millennium Pharmaceuticals in Cambridge, Massachusetts. He then moved to Tempo Pharmaceuticals (Cerulean Pharmaceuticals) before joining Novartis in January 2009, where he held leadership positions in ocular PK/IG, the PK/PD/IG of biologics, and gene therapies, as well as representing PKS Sciences on the Cell & Gene Therapy Steering Committee and Novartis’s First in Human Review Board. Dr. Milton held a leadership position in the AAV Immunogenicity Task Force and the Immunogenicity Advisory Group. Dr. Milton supported many of Novartis’s gene therapy projects and anti-complement programs, wrote the nonclinical PK summary for the Kymriah BLA, was involved in the in-licensing of Luxturna and the acquisitions of Avexis and Gyroscope, and provided nonclinical and clinical PK and immunogenicity support to Zolgensma post-market and for intrathecal administration of OAV101.

    Dr. Milton is a past chair of the BioSafe PKPD EWG, a member of the BioSafe LC and IQ Board of Directors, a member of the AAPS Pre-existing Antibody and Immunogenicity Risk Assessment Working Groups, and was the BIO observer to the ICHS3A Q&A WG.

    He has published over 30 peer-reviewed publications and book chapters and presented extensively on the development of NCEs, biologics, and gene therapies. His interests include the PK/PD and immunogenicity of biotherapeutics, the contribution of PK (biodistribution) and IG to the development of gene therapies, ocular immunology, the selection of the clinical starting dose based upon the MABEL calculation, and alternative designs for FIH clinical trials of monoclonal antibodies in healthy volunteers.

    Jay Tibbitts, DVM, PhD

    Jay Tibbitts, DVM, PhD

    Executive Director of Drug Metabolism and Pharmacokinetics

    Gilead Sciences, Inc.

    Dr. Jay Tibbitts is an Executive Director in the Drug Metabolism and Pharmacokinetics Department at Gilead Sciences. Prior to joining Gilead, he led Nonclinical PKPD organizations at AbbVie, UCB, and Genentech, led Nonclinical Development, and served as a Project Leader at both Surrozen, Inc and Lycia Therapeutics. He has dedicated much of his career to the quantitative pharmacology and development of both small- and large-molecule drugs across multiple indications, and has contributed to the filing of more than 20 INDs and several BLAs. Dr. Tibbitts received his PhD in pharmaceutical chemistry from the University of California, San Francisco, and a DVM from Ohio State University.

    John L. Vahle, DVM, PhD, Diplomate ACVP

    John L. Vahle, DVM, PhD, Diplomate ACVP

    Senior Research Fellow

    Eli Lilly and Company

    Dr. John Vahle received his veterinary medical degree from the University of Missouri in 1988 and his doctorate in veterinary pathology from Iowa State University in 1996.  He became a Diplomate of the American College of Veterinary Pathologists in 1995 and joined Lilly as a senior pathologist in 1996. He currently serves as a Senior Research Fellow at Lilly.

    Dr. Vahle has over 25 years of experience in pathology and toxicology and has served in a variety of roles including study pathologist, project pathologist, toxicology project leader, and regulatory toxicology advisor.  His areas of interest include carcinogenicity assessments, biotherapeutics development, bone toxicology, and pathology. Dr. Vahle is active in various professional societies and consortia and is a past Councilor of the STP, past Chair of the BioSafe Organization, and a member of the steering committee for the international toxicologic pathology nomenclature initiative, INHAND.  Based on his experience in carcinogenicity testing, Dr. Vahle served as a member of the ICH Expert Working Group assessing carcinogenicity testing paradigms for pharmaceuticals. Dr. Vahle’s publications have focused on toxicologic pathology of the endocrine and musculoskeletal systems as well as approaches to carcinogenicity assessment.

    Mary Ellen Cosenza, PhD, MS, DABT, ATS, ERT, RAC, MEC Regulatory & Toxicology Consulting, LLC

    Jeanine Bussiere, PhD, DABT, ATS, Amgen Inc.

    Buay Permpoontaweesup, ACT Staff Liaison

    Registration Fees

    Early-Bird Registration
    (Received by April 22)
    Regular Registration
    (Begins April 23)
    ACT Member $1,650 $1,750
    ACT Student or Postdoc Member $895 $995
    Nonmember $1,950$2,050
    Government* $1,650 $1,750
    ACT Member Group Rate**
    (3 or more from same company)
    $1,550$1,650
    ACT Member Group Rate**
    (10 or more from same company)
    $1,450$1,550
    Nonmember Group Rate**
    (3 or more from same company)
    $1,750 $1,850
    Nonmember Group Rate**
    (10 or more from same company)
    $1,650$1,750

    Fees are accessed according to the membership status at the time of purchase (there are no exceptions and there are no refunds).

    *Government Registration Policy: The government registration rate is specifically designated for federal, state, or local employees of government departments/agencies who are actively participating in the course as official government personnel. Employees of public academic institutions, nonprofit institutions, or government contractors do not qualify for the discounted government rate. To register under the government rate, individuals must use their government-affiliated email address for verification purposes. ACT may request further documentation of government employment before the registration is finalized. If you are unsure you qualify for the government rate, please email ACT Headquarters before processing your payment online.

    **Group Rate Registration: To take advantage of the group rate: Please send your completed registration forms to ACT Headquarters. You will not be able to select the group rate through the online registration. All three forms (or more) should be emailed at the same time.

    Refund Policy: $100 Processing Fee will be charged if canceled before June 11, 2027, 50% refund if canceled before July 9, 2027; After July 10, 2027, no fees will be refunded. 

    Register

    Registration Form

    Course Location

    Gaithersburg Marriott Washingtonian Center
    9751 Washingtonian Boulevard
    Gaithersburg, MD 20878

    Transportation Information

    Hotel

    Gaithersburg Marriott Washingtonian Center
    9751 Washingtonian Boulevard
    Gaithersburg, MD 20878
    Tel: 301.590.0044 | 301.590.6104

    Housing Deadline

    Please refer to the ACT Room Block to make your housing reservation. The ACT meeting rate of $199 (plus tax) is offered over the dates of June 13–16, 2027, based on availability, and reservations must be made by May 14, 2027.

    Daily continental breakfast, snack breaks, and lunch are provided as part of the registration. To disclose dietary restrictions, allergies, and/or accessibility needs please email ACT Headquarters by May 14, 2027. ACT will do its best to accommodate but cannot guarantee requests will be granted.

    • You must log in to register
      • Early bird pricing available!
      • Nonmember - $1,950
      • Full Member - $1,650
      • Associate Member - $1,650
      • Emeritus Member - $1,650
      • Government Associate Member - $1,650
      • Government Full Member - $1,650
      • Postdoctoral Researcher/Transitional Member - $895
      • Student Member - $895
      • Regular Price after 04/22/2027 11:59 PM
      • Nonmember - $2,050
      • Full Member - $1,750
      • Associate Member - $1,750
      • Emeritus Member - $1,750
      • Government Associate Member - $1,750
      • Government Full Member - $1,750
      • Postdoctoral Researcher/Transitional Member - $995
      • Student Member - $995
    • More Information
  • Contains 1 Component(s) Includes a Live In-Person Event on 06/14/2027 at 8:00 AM (EDT)

    Course will be held in Gaithersburg, Maryland, from June 14–16, 2027. More information about the schedule and registration will be available soon.

    This ACT course offers an in-depth exploration of regulatory considerations and the toxicologic evaluation and development of protein biologics, modified protein biologics, and specialized biologics, including cell and gene therapies, and oncolytic viruses. Participants gain a thorough understanding of the key principles and methodologies employed in the nonclinical safety assessment of these advanced therapeutic modalities. The curriculum covers a wide range of studies essential for advancing biotherapeutic drug candidates through all stages of drug development from candidate selection to marketing authorization. Topics include general toxicity studies and a variety of specialized studies, such as off-target assessment, safety pharmacology, carcinogenicity, and reproductive and developmental toxicity studies. Additionally, the course provides insight into pharmacokinetic and biodistribution assessments and the potential impact of immunogenicity for various of different therapeutic modalities. Several case studies are used to highlight how specific strategies and issues are approached in different scenarios.

    The course will be held in Gaithersburg, Maryland, from June 14–16, 2027. More information about the schedule and registration will be available soon.

    This ACT course is offered exclusively in person. Virtual or hybrid participation options are not available.

    • You must log in to register
      • Early bird pricing available!
      • Nonmember - $1,950
      • Full Member - $1,650
      • Associate Member - $1,650
      • Emeritus Member - $1,650
      • Government Associate Member - $1,650
      • Government Full Member - $1,650
      • Postdoctoral Researcher/Transitional Member - $895
      • Student Member - $895
      • Regular Price after 04/22/2027 11:59 PM
      • Nonmember - $2,050
      • Full Member - $1,750
      • Associate Member - $1,750
      • Emeritus Member - $1,750
      • Government Associate Member - $1,750
      • Government Full Member - $1,750
      • Postdoctoral Researcher/Transitional Member - $995
      • Student Member - $995
    • More Information
  • COMING SOON
    Contains 4 Product(s)

    Modules explore genetic toxicology assays, positive result interpretation, regulatory considerations, and practical decision making through real-world case studies.

    This eLearning seminar focuses on genetic toxicology, with an emphasis on navigating challenges associated with positive assay results. Each module covers a core component of the genetic toxicology battery—including in silico assessments, Ames, in vitro micronucleus, and in vivo genetic toxicology assays such as comet and in vivo micronucleus—and addresses relevant guidance, assay design, and their application in drug development. The series goes beyond the fundamentals to explore advanced topics such as historical control data, assay-specific data analysis best practices, and study design factors that influence result interpretation. Case studies illustrate strategies for managing positive findings, including follow-up study options and regulatory considerations. Overall, the series aims to provide participants with practical tools and real-world examples to support informed decision making in genetic toxicology.

    These modules feature presentations by recognized experts in the field. Modules are available for purchase as a set. Once the live module presentations conclude, registrants will have on-demand access to the modules for 30 days from the time each archive is first accessed. Each module is approximately 90 minutes.

    Disclaimer:
    This seminar reflects the views of the speaker and should not be construed to represent the views or policies of the American College of Toxicology. Examples presented in this seminar may have required unique strategies that do not necessarily apply to other modalities or situations. Regulatory guidelines and best practices are constantly evolving, and the viewer is encouraged to independently confirm their understanding with what was presented in this seminar.

    Registration Fees:

    Seminar registration is restricted to single person use only. Please note that all eLearning sales are final. Fees are assessed according to membership status at the time of purchase. No cancellations or refunds will be allotted after payment is processed.

    Registration Type Set/Module 1–4
    ACT Member $225
    ACT Student/Transitional/Postdoctoral Researcher Member $125
    Nonmember $350

    The Are You Positive? Navigating Genetic Toxicology Challenges eLearning seminar content will only be available until December 31, 2029.

    • You must log in to register
      • Nonmember - $350
      • Full Member - $225
      • Associate Member - $225
      • Emeritus Member - $225
      • Government Associate Member - $225
      • Government Full Member - $225
      • Postdoctoral Researcher/Transitional Member - $125
      • Student Member - $125
    • More Information
  • COMING SOON
    Contains 4 Product(s)

    Modules explore genetic toxicology assays, positive result interpretation, regulatory considerations, and practical decision making through real-world case studies.

    This eLearning seminar focuses on genetic toxicology, with an emphasis on navigating challenges associated with positive assay results. Each module covers a core component of the genetic toxicology battery—including in silico assessments, Ames, in vitro micronucleus, and in vivo genetic toxicology assays such as comet and in vivo micronucleus—and addresses relevant guidance, assay design, and their application in drug development. The series goes beyond the fundamentals to explore advanced topics such as historical control data, assay-specific data analysis best practices, and study design factors that influence result interpretation. Case studies illustrate strategies for managing positive findings, including follow-up study options and regulatory considerations. Overall, the series aims to provide participants with practical tools and real-world examples to support informed decision making in genetic toxicology.

    These modules feature presentations by recognized experts in the field. Modules are available for purchase as a set. Once the live module presentations conclude, registrants will have on-demand access to the modules for 30 days from the time each archive is first accessed. Each module is approximately 90 minutes.

    Disclaimer:
    This seminar reflects the views of the speaker and should not be construed to represent the views or policies of the American College of Toxicology. Examples presented in this seminar may have required unique strategies that do not necessarily apply to other modalities or situations. Regulatory guidelines and best practices are constantly evolving, and the viewer is encouraged to independently confirm their understanding with what was presented in this seminar.

    • You must log in to register
      • Nonmember - $350
      • Full Member - $225
      • Associate Member - $225
      • Emeritus Member - $225
      • Government Associate Member - $225
      • Government Full Member - $225
      • Postdoctoral Researcher/Transitional Member - $125
      • Student Member - $125
    • More Information
  • Contains 1 Component(s) Includes a Live In-Person Event on 04/26/2027 at 8:00 AM (EDT)

    Course will be held in Gaithersburg, Maryland, from April 26–30, 2027. More information about the schedule and registration will be available soon.

    This annual ACT course provides basic training in general toxicology. Participants obtain an overall understanding of the principles of toxicology and nonclinical safety evaluation, with a focus on pharmaceutical development. The course includes a mix of lectures with breakout group discussions of regulatory case studies and hands-on analyses of nonclinical data to give participants the opportunity to apply the concepts of toxicology in the context of drug development. The course is intended to benefit individuals working with small and large molecules from biotechnology and pharmaceutical companies, CROs, and regulatory agencies, or individuals interested in or currently practicing toxicology

    The ACT course is offered exclusively in person. Virtual or hybrid participation options are not available.

    Monday, April 26, 2027

    Principles of Toxicology, A. Wallace Hayes, University of South Florida, College of Public Health

    Introduction to Drug Development Toxicology, Natalie Holman, Eli Lilly and Company

    Introduction to Pharmacology for the Toxicologist, Amy Avila, US FDA

    Principles of Drug Metabolism and Toxicokinetics and Applications to Pharmaceutical Toxicology, Leanne Bedard, Bedard ADME-Tox Solutions

    Safety Pharmacology for Human Pharmaceuticals, Simon Authier, Charles River Laboratories

    Reception

    Please join us for a reception following the course on Monday. This light-fare reception, which is included in the registration fee, allows for fellow course attendees, course organizers, and speakers to interact and network in a casual atmosphere. 

    Tuesday, April 27, 2027

    General Toxicology, Lorrene Buckley, Eli Lilly & Company

    Toxicology of Organ Systems, Mary Beth Genter, University of Cincinnati

    Regulatory Toxicology—A Nonclinical Pharmacology and Toxicology Perspective, Arianne Motter, US FDA

    Practical Application: Breakout Session to Review Cases, Hanan Ghantous, US FDA, Natalie Holman, Eli Lilly and Company

    Wednesday, April 28, 2027

    Clinical Pathology: Principles for Pharmaceutical and Regulatory Scientists, Kazuhisa Miyakawa, Johnson & Johnson

    Pathology in Toxicology Studies, Debra Tokarz, Genentech, Inc.

    Cell and Gene Therapy, Melanie Hartsough, Hartsough Nonclinical Consulting, LLC

    Nonclinical Safety Evaluation of Biotechnology-Derived Therapeutics, Melanie Hartsough, Hartsough Nonclinical Consulting, LLC

    Thursday, April 29, 2027

    Genetic Toxicology, Zhanna Sobol, Merck and Co.

    Evaluation of Potential Carcinogenicity, Timothy McGovern, White Oak Regulatory Tox, LLC

    Reproductive/Developmental and Juvenile Toxicology, Alan Hoberman, Argus International, Inc.

    Risk Assessment, Melissa Rhodes, Avalyn Pharma  

    Friday, April 30, 2027*

    Immunotoxicology, Florence Burleson, Burleson Research Technologies, Inc. 

    Label Review of Drug P, Hanan Ghantous, US FDA

    Review of Drug P Program: History and Outcome

    *Course ends at noon.

    Speakers, presentation topics, and/or format are subject to change.

    Detailed course handouts will be provided electronically. Participants must bring a personal computer to view materials. Please ensure to download materials before arriving. Internet will not be provided.

    Times:

    Registration and Check-In: Monday, 7:30 AM–8:00 AM

    Reception: Monday (Time to be confirmed)

    Course Presentations:

    Monday, 8:00 AM–4:15 PM;
    Tuesday–Wednesday, 8:00 AM–5:00 PM;
    Thursday, 7:45 AM–5:30 PM;
    Friday, 8:00 AM–12:00 Noon

    Simon Authier, DVM, MSc, MBA, PhD, DSP

    Simon Authier, DVM, MSc, MBA, PhD, DSP

    Executive Director of Scientific Innovation and Partnerships

    Charles River Laboratories

    Dr. Simon Authier obtained a Doctor of Veterinary Medicine degree from the University of Montreal and specialized in nonclinical studies after completing a PhD in nonclinical pharmacology. He then completed an MBA in corporate finance and management. Dr. Authier is an Executive Director of Scientific Innovation and Partnerships at Charles River Laboratories, where he leads drug development programs across a broad range of modalities. He has been an invited speaker at various scientific conferences, including the American College of Toxicology, the Safety Pharmacology Society, the Japanese Society of Safety Pharmacology, the American Association of Laboratory Animal Science, and the US Food and Drug Administration. Dr. Authier is an Associate Professor at the Faculty of Veterinary Medicine at the University of Montreal, where he is involved with clinical immunology and pharmacology, and he has authored more than 150 peer-reviewed articles and book chapters. To date, Dr. Authier has provided scientific overviews for more than 1,400 nonclinical studies for small molecules, biologics, and cell therapies. He is a past President of the Safety Pharmacology Society (SPS), is a board-certified safety pharmacologist (DSP), and currently serves as the ACT Secretary. Over the years, he has volunteered and participated in various ACT initiatives, including educational sessions.

    Amy M. Avila, PhD

    Amy M. Avila, PhD

    Pharmacologist/Toxicologist Reviewer, Division of Psychiatry Products, CDER

    US FDA

    Dr. Avila earned her Bachelor of Science degree in Biochemistry from the University of Delaware. She then received her PhD in pharmacology from Georgetown University, with a focus in neuropharmacology. Her thesis research involved the study of neuronal nicotinic acetylcholine receptors and their functional regulation by nicotine and nerve growth factor. After receiving her PhD, she conducted postdoctoral research at the National Institute of Neurological Disorders and Stroke at the National Institutes of Health. She worked in the Neurogenetics Branch studying the neuromuscular disease Spinal Muscular Atrophy and investigating possible pharmacological therapies using cell-based models and transgenic mouse models. In 2006, Dr. Avila joined the Food and Drug Administration where she is currently serving as a pharmacologist/toxicologist reviewer in the Division of Psychiatry Products in the Center for Drug Development and Research (CDER). She is an active member of the Committee for Advanced Scientific Education in CDER, was a member of the Education Subcommittee of the Pharmacology/Toxicology Coordinating Committee, and has contributed to the development of a training course for new pharmacologist/toxicologist reviewers. Her areas of interest are psychopharmacology, and assessment of seizures in nonclinical drug development.

    Leanne Bedard, PhD, RAC, DABT

    Leanne Bedard, PhD, RAC, DABT

    Consultant

    Bedard ADME-Tox Solutions

    Dr. Leanne Bedard received her PhD in Pharmacology and Toxicology from Queen’s University (Kingston, ON, Canada) in 2004. Dr. Bedard began her career in pharmaceutical research in 2006 at Merck Frosst in Montréal, where she was the recipient of a Special Achievement Award for her contribution to the discovery of PIFELTRO™, a non-nucleoside reverse transcriptase inhibitor, now marketed for the treatment of HIV. Dr. Bedard then joined AstraZeneca R&D Montréal as a DMPK Drug Design Leader. For over 15 years, Dr. Bedard has worked as an independent consultant in nonclinical drug metabolism, pharmacokinetics, and toxicology. She has worked with numerous biotech and small pharma companies located in Canada and in the US. She has contributed to the discovery, nonclinical development, and successful regulatory filing of several small molecule investigational new drugs and marketing authorizations in jurisdictions worldwide (USA, Europe, UK, Canada, Australia and Japan). Dr. Bedard has also served as a Nonclinical Pharm/Tox Reviewer to the Pharmaceutical Drugs Directorate at Health Canada.

    Dr. Bedard is a Diplomate of ABT and holds a certification in Regulatory Affairs. She is the sole author of the book chapter on Toxicokinetics for the revised 7th Edition of the quintessential toxicology textbook, Hayes’ Principles and Methods of Toxicology. Dr. Bedard is also a speaker in ACT’s Advanced Comprehensive Toxicology course and was an invited speaker in the Drug Discovery in Neuroscience seminar series at Harvard Medical School/Boston Children’s Hospital. She has served on ACT’s Program Committee and is currently an ACT Councilor. In the past, Leanne has also served other scientific societies in various roles, including the Society of Toxicology, the Society of Toxicology of Canada, the International Society for the Study of Xenobiotics, and the Roundtable of Toxicology Consultants.

    Lorrene A. Buckley, PhD, DABT, ATS

    Lorrene A. Buckley, PhD, DABT, ATS

    Vice President

    Eli Lilly & Company

    Dr. Lorrene Buckley is a board-certified toxicologist with over 30 years of experience in the active practice of toxicology. She earned her degrees in Toxicology, an MS from the University of Arizona, and a PhD from the University of North Carolina at Chapel Hill, in collaboration with the laboratories of the NIEHS and US EPA. She is certified by the American Board of Toxicology (ABT) and is a Fellow of the Academy of Toxicological Sciences (ATS).

    Dr. Buckley’s diversity of professional experience as a toxicologist is reflected in her work spanning basic and applied toxicology research and risk assessment in the industrial chemical, agrochemical, and pharmaceutical industries. As a Vice President at Eli Lilly & Company, she was responsible for the design and execution of nonclinical safety assessment programs as well as for nonclinical aspects of global regulatory submissions and interactions for drugs in the development and commercialization phases. Dr. Buckley has authored the pharmacology/toxicology sections of numerous regulatory documents, including briefing documents, INDs/IMPDs, BLAs/NDAs, investigator brochures, annual reports, as well as safety information on product labels/package inserts.

    Her contributions to the profession of toxicology include service on the Boards of the ABT and the ATS (past President) and on the Councils of the ACT (past President) and the SOT.

    Florence G. Burleson, PhD

    Florence G. Burleson, PhD

    Consultant

    Burleson Research Technologies, Inc.

    Dr. Burleson received her PhD from the Department of Microbiology at the University of Notre Dame and a Master of Science in Financial Management and Technology Commercialization from North Carolina State University (NCSU). She has more than 30 years of professional experience in government, pharmaceutical, and contract research. She is the co-founder of Burleson Research Technologies, Inc. (BRT), a CRO specializing in immunotoxicology. Dr. Burleson has served as a Study Director conducting GLP-compliant studies for immunological, functional, and host resistance immunotoxicity assessments. As Executive VP and Senior Director of Nonclinical Studies, she provides oversight and direction for nonclinical studies programs and is responsible for budgets and financial management at BRT.

    Dr. Burleson is a member of the American College of Toxicology (ACT) and Society of Toxicology (SOT), and a Fellow of the Academy of Toxicological Sciences (ATS). She was elected to the ACT Outreach Committee in 2013 and the ACT Council in 2016. She was Vice-President, President-Elect, and President (2022-2023) of ACT. She has also served on the SOT Finance Committee and is a past President of the SOT Immunotoxicology Specialty Section. Dr. Burleson was Chair of the Scientific Liaison Coalition (SLC), a coalition of societies to increase the impact of the science of toxicology to improve public health. She currently serves on the Editorial Board of the International Journal of Toxicology and on the Editorial Board of Toxicology Research Application.

    Mary Beth Genter, PhD, DABT, ATS

    Mary Beth Genter, PhD, DABT, ATS

    Professor

    University of Cincinnati

    Dr. Mary Beth Genter is a board-certified toxicologist with an interest in all areas of toxicology, with a focus on neurotoxicology and respiratory tract toxicology. Prior to joining the University of Cincinnati Department of Environmental Health (now the Department of Environmental and Public Health Sciences), Dr. Genter earned her PhD from the Integrated Toxicology Program at Duke University, received postdoctoral training at CIIT, and was an Assistant, then Associate Professor in the North Carolina State University Department of Toxicology. Dr. Genter has published over 100 peer-reviewed manuscripts, reviews, and book chapters. Dr. Genter has recently retired from full-time work at the University of Cincinnati as Professor Emerita, while continuing to teach online. She is currently (2009–present) Editor-in-Chief of International Journal of Toxicology, the official journal of the American College of Toxicology. Other service to the field of toxicology includes past participation as a member of the North Carolina Secretary’s Scientific Advisory Board on Toxic Air Pollutants; service as an advisor to the US EPA for the IRIS reevaluation of naphthalene; service as a member of the ABT Board of Directors (2004–2008); service on the National Toxicology Program Board of Scientific Counselors (2013–2017); participation on the IARC Monograph Volume 140 panel (2025); and as a member of the National Academies Committee on Review of Methods in the Report on Carcinogens Handbook (2026).

    Hanan Ghantous, PhD, DABT

    Hanan Ghantous, PhD, DABT

    Division Director for Pharmacology/Toxicology for Infectious Diseases

    US FDA

    Dr. Hanan Ghantous is the Division Director for Pharmacology/Toxicology for Infectious Diseases (DPT-ID) at the US Food and Drug Administration (US FDA). She joined US FDA as a pharmacology/toxicology reviewer in 2001, and since 2007, she has been the Pharmacology/Toxicology supervisor at the Division of Antiviral Products, Center for Drug Evaluation and Research. Dr. Ghantous has presented at national and international scientific and regulatory meetings, has served on several US FDA committees, has been involved in writing Guidance documents, and has represented the agency at various public forums. She has been mentoring local and international pharmacy interns since she joined US FDA. Before coming to US FDA, Dr. Ghantous worked at the DuPont Company for approximately 10 years.

    Dr. Ghantous has been a member of ACT since 2000. She has served on many committees over the years, as well as on Council (2011–2013) and as ACT Vice President-Elect, Vice President, President, and Past President (2014–2017). She also has been a member of the Society of Toxicology (SOT) since 1989. She served on the Continuing Education Committee of SOT (2010–2013). Dr. Ghantous is one of the founders of the Biotechnology Specialty Section and served as Vice President-Elect, Vice President, President, and Past President of the Specialty Section (2010–2013). She also served as a member of the Board of Directors of the American Board of Toxicology (ABT) (2010–2014) and was the President of the board for 2013–2014. She was recognized by ACT as the first recipient of the prestigious ACT Mildred Christian Women’s Leadership in Toxicology Award in 2018.

    Dr. Ghantous received a BSc in pharmacy from the University of Baghdad, Iraq; an MSc in pharmacology from the University of Strathclyde, Scotland; and a PhD in toxicology from the University of Uppsala, Sweden. She was a postdoctoral fellow in the Department of Anesthesiology, University of Arizona, and received her board certification as a Diplomate of the American Board of Toxicology (DABT) in 1995. Dr. Ghantous has over 30 years of combined experience in general and regulatory toxicology.

    Melanie T. Hartsough, PhD

    Melanie T. Hartsough, PhD

    Consultant

    Hartsough Nonclinical Consulting, LLC

    Dr. Melanie Hartsough received her PhD in Pharmacology from Pennsylvania State University, College of Medicine. After a postdoctoral fellowship at NIH, she joined US FDA’s Center for Biologics Evaluation and Research (CBER), Division of Therapeutic Proteins, as a full-time product reviewer where she performed chemistry, manufacturing, and controls (CMC) and immunogenicity reviews for biotechnology-derived products. In 2004, Dr. Hartsough transferred to the Division of Biologic Oncology Products, Center for Drug Evaluation and Research (CDER), as a pharmacology/toxicology reviewer. During this time, she also performed consult reviews for the Office of Vaccines Research and Review and Office of Blood Research and Review, CBER. In 2006, she left the US FDA and joined Aclairo Pharmaceutical Development Group, Inc as a consultant. In 2007, she left Aclairo and joined the Biologics Consulting Group, Inc. In 2017, Dr. Hartsough founded Hartsough Nonclinical Consulting, LLC to provide scientific, regulatory and strategic advice associated with nonclinical pharmacology, pharmacokinetic and toxicology development of biologic biopharmaceuticals and small molecule products.

    Dr. Hartsough is a member of ACT and American Society of Gene and Cell Therapy and has served on the ACT Nominating Committee. She has been a guest speaker for a variety of courses and scientific meetings and has authored or coauthored book chapters covering topics such as therapeutic vaccines, biopharmaceutics, immunogenicity, peptide and protein nonclinical development and relevant species selection.

    A. Wallace Hayes, PhD, DABT, ATS, FIBiol, FACFE, ERT

    A. Wallace Hayes, PhD, DABT, ATS, FIBiol, FACFE, ERT

    Professor

    University of South Florida, College of Public Health

    Dr. A. Wallace Hayes is a distinguished toxicologist with more than 40 years of experience across academia and industry. He earned his PhD and MS degrees from Auburn University and his AB from Emory University. His early scientific training included service as a National Science Foundation predoctoral fellow at Auburn University, a National Institutes of Health individual postdoctoral fellow at Vanderbilt University School of Medicine, a NATO Senior Scientist at the Central Veterinary Laboratory in Weybridge, England, and a recipient of an NIH Research Career Development Award at the University of Alabama.

    Dr. Hayes has held tenured professorships at the University of Alabama, the University of Mississippi Medical Center, and Wake Forest University School of Medicine. His industry leadership roles have included Director of Toxicology and Regulatory Affairs at Rohm and Haas, Vice President at RJR Nabisco, and Corporate Vice President at the Gillette Company. He has also contributed his expertise to committees and expert panels convened by the National Academy of Sciences, the National Institutes of Health, the Environmental Protection Agency, the Food and Drug Administration, and the Department of Defense.

    Dr. Hayes has authored more than 460 peer-reviewed publications. He is editor of Hayes’ Principles and Methods of Toxicology, 7th edition, Human and Experimental Toxicology, and Cutaneous and Ocular Toxicology; co-editor of the Target Organ Toxicity series; and co-author of the 4th and 5th editions of Loomis’s Essentials of Toxicology. His professional leadership includes two terms as Secretary-General of the International Union of Toxicology; service as treasurer and board member of the American Board of Toxicology; presidencies of the American College of Toxicology, the Toxicology Education Foundation, and the Academy of Toxicological Sciences; and membership on the council of the Society of Toxicology. He is a diplomate of the American Board of Toxicology, the Academy of Toxicological Sciences, the American Board of Forensic Medicine, and the American Board of Forensic Examiners. He is also a Fellow of the Academy of Toxicological Sciences, the Royal Society of Medicine (UK), the American College of Forensic Examiners, and the American College of Nutrition. He is also a registered toxicologist in the European Union (ERT) and a certified nutrition specialist in food safety. Dr. Hayes’ honors include the Society of Toxicology Merit Award (2006), the Mid-Atlantic Society of Toxicology Ambassador Award (2012), the American College of Toxicology Distinguished Scientist Award (2012), and the Nancy Rollman Service Award (2026), the International Dose-Response Society Outstanding Leadership Award (2013), and the American Academy of Toxicology Mildred S. Christian Career Achievement Award (2021). He was named a Distinguished Fellow of the American College of Toxicology in 2013 and a Fellow of the American Association for the Advancement of Science in 2014.

    Alan M. Hoberman, PhD, DABT, ATS

    Alan M. Hoberman, PhD, DABT, ATS

    President

    Argus International, Inc.

    Dr. Alan Hoberman has been employed by Charles River Laboratories, Horsham, Pennsylvania (formerly Argus Research Laboratories, Inc.) since 1981, serving as Study Director, Director of Reproductive Toxicology, Executive Director, Global Developmental, Reproductive and Juvenile Toxicology and Scientific Advisor. He is also the President of Argus International Inc. a consulting company. Prior to joining Argus Research, Dr. Hoberman was the Head of Reproductive Toxicology at Hazleton Laboratories in Vienna, Virginia. He received his BS in Biology from Drexel University and was a graduate student in Anatomy at the University of Virginia before moving to Arkansas and completing a MS in Interdisciplinary Toxicology from the University of Arkansas and a PhD in Toxicology from Pacific Western University.

    He is a Diplomat of the American Board of Toxicology since 1988 and a Fellow of the Academy of Toxicological Sciences since 2006, with over 95 publications and book chapters. He is the co-editor of “Pediatric Non-Clinical Drug Testing, Principles, Requirements, and Practices” published in January 2012.

    Dr. Hoberman has been a member of Birth Defects Research and Prevention since 1978 and is a Past President. He is also a member of the European Teratology Society since 1982 and past councilor. He has been a member of the American College of Toxicology since 1979 and is a Past President. He is a Past President of the Reproductive and Developmental Toxicity Specialty Section of the Society of Toxicology, the Middle Atlantic Reproductive and Teratology Association, and the Arkansas Biotechnology Organization. He currently represents the 3Rs Collaborative on the Scientific Liaison Collation.

    Natalie Holman, PhD, DABT

    Natalie Holman, PhD, DABT

    Director of Nonclinical Safety Assessment

    Eli Lilly and Company

    Dr. Natalie Holman is a board-certified toxicologist at Eli Lilly and Company. As a Toxicology Project Leader at Lilly, Dr. Holman is responsible for nonclinical safety assessment strategies and regulatory interactions supporting discovery- and clinical-stage assets in multiple therapeutic areas. Her role also includes due diligence assessments for in-licensing opportunities and contributing to development of platform approaches for toxicity assessment of novel therapeutic modalities. Prior to joining Lilly, she was a project toxicologist at Altavant Sciences and its affiliate Roivant Sciences, where she supported molecules across the portfolio of several subsidiaries. Dr. Holman serves on cross-industry working groups and is an active member of several professional toxicology societies. As a member of ACT, she has served as a speaker and chair for symposia and CE courses, held elected positions on multiple committees, chaired the ACT Early Career Professionals Subcommittee, and received the ACT Early Career Professional Award. Dr. Holman received her PhD in Toxicology and Certificate in Translational Medicine from the University of North Carolina Chapel Hill School of Medicine. She conducted her doctoral research in mechanistic hepatotoxicity at The Hamner Institutes for Health Sciences (formerly Chemical Industry Institute of Toxicology, CIIT).

    Timothy McGovern, PhD

    Timothy McGovern, PhD

    Principal Consultant

    White Oak Regulatory Tox, LLC

    Dr. Timothy McGovern is a co-founder and Principal Consultant of White Oak Regulatory Tox, LLC, where he provides advice to pharmaceutical companies related to all aspects of nonclinical programs intended to support pharmaceutical drug development from first in human clinical trials to marketing applications.

    Dr. McGovern recently completed a 22-year career at the US Food and Drug Administration (FDA) where he spent the past 11 years as an Associate Director for Pharmacology and Toxicology in the Office of New Drugs (OND) of the Center for Drug Evaluation and Research (CDER). He served as a member of the Pharmacology/Toxicology Senior Leadership Team within OND and was responsible for the development of policy and guidance related to nonclinical and regulatory issues including FDA and International Council for Harmonization (ICH) guidance initiatives. He was also a standing member of CDER’s Executive Carcinogenicity Assessment Committee as well as CDER’s Genetic Toxicology and Pharmacology/Toxicology Education Subcommittees.

    Dr. McGovern was a member of multiple ICH Expert Working Groups including S1B (Testing for Carcinogenicity of Pharmaceuticals), M7 (DNA reactive impurities), Q3C (Residual Solvents), and Q3D (Elemental Impurities), serving as Topic Lead and Rapporteur. Dr. McGovern was also a member of CDER’s Task Force on Nitrosamines in Drug Products providing nonclinical expertise in developing policies, addressing clinical safety issues, and interacting with other Drug Regulatory Agencies and Industry stakeholders. He participated in drafting FDA’s Guidances “Control of Nitrosamine Impurities in Human Drugs” and “Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs)” and served as Chair of the CDER Pharm/Tox Nitrosamines Working Group.

    Dr. McGovern earned a doctorate degree in inhalation toxicology from New York University and first joined OND’s Division of Pulmonary and Allergy Products (DPAP) as a primary reviewer. He later supervised review teams in DPAP as well as the Division of Anesthetic and Critical Care Products.

    Kazuhisa Miyakawa, BVSc (DVM), PhD, DACVP, DABT

    Kazuhisa Miyakawa, BVSc (DVM), PhD, DACVP, DABT

    Senior Clinical Pathologist, Clinical Pathology and Safety Biomarkers

    Johnson & Johnson

    Dr. Kazuhisa (Kaz) Miyakawa is a board-certified veterinary clinical pathologist (DACVP) and toxicologist (DABT) with over 10 years of experience in safety assessment, specializing as a toxicology clinical pathologist and compound leader.  

    He earned his BVSc (equivalent to a DVM) and worked as a private-practice veterinarian in Japan for seven years. After relocating to the United States, Dr. Miyakawa completed the ECFVG program at Purdue University, a clinical pathology residency at Michigan State University, and earned his PhD in Pathology and Toxicology from Michigan State University. His previous roles include positions at Toxikon (now Labcorp) and Merck. Currently, he is a target clinical pathologist within the Clinical Pathology and Safety Biomarkers team in the department of Predictive Safety and Translational Sciences at Johnson & Johnson. 

    His primary research interest lies in translational fluid biomarkers applicable to both nonclinical species and humans. 

    Arianne Motter, PhD, DABT

    Arianne Motter, PhD, DABT

    Senior Toxicologist, Division of Pharmacology/Toxicology for Infectious Diseases

    US FDA

    Dr. Arianne Motter is a board-certified toxicologist with 15 years of expertise in the field. She currently serves in the Division of Pharmacology and Toxicology for Infectious Diseases within CDER at the FDA, where she is responsible for reviewing pre-IND, IND, EUA, NDA, and BLA submissions related to antiviral products. In addition to these duties, Dr. Motter contributes to educational initiatives, serves on both the neurotoxicology and pharmacokinetic subcommittees, and assists in the development of resources to support SEND submissions. Before joining the FDA in 2014, she was a toxicologist with the Armed Forces Medical Examiner. Dr. Motter holds a BS in Chemistry from West Chester University in Pennsylvania and earned her PhD in Pharmacology from Georgetown University in 2011. She is also an associate professor in the Department of Pharmacology and Physiology at Georgetown University, where she lectures on drug toxicity to medical and graduate students.

    Melissa Rhodes, PhD, DABT

    Melissa Rhodes, PhD, DABT

    Chief Operating Officer

    Avalyn Pharma

    Dr. Melissa Rhodes is the Chief Operating Officer at Avalyn Pharma, a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary diseases. Prior to joining Avalyn, she held the position of Chief Development Officer at Kriya Therapeutics (a gene therapy company), at Aerami Therapeutics (an inhaled biologics company) and at Altavant Sciences (a rare respiratory disease company). Previously, Dr. Rhodes served as Senior Vice President of Nonclinical Research at Roivant Sciences. She spent almost 10 years at GSK in Safety Assessment and started in drug development at a biotech university spin-out in oncology. Dr. Rhodes completed a postdoctoral fellowship at the National Toxicology Program at the National Institute of Environmental Health Sciences, holds a PhD in pharmacology and toxicology from Duke University Medical Center, and is a Diplomate of the American Board of Toxicology. 

    Zhanna Sobol, PhD

    Zhanna Sobol, PhD

    Director of Genetic Toxicology

    Merck and Co., Inc.

    Dr. Zhanna Sobol is an applied genetic toxicologist with over 17 years of experience in the pharmaceutical industry. She holds a Bachelor of Science degree in Microbiology and Molecular Genetics and a PhD in Molecular Toxicology from the University of California, Los Angeles. During her graduate work, she studied mechanisms of DNA damage and repair while incorporating key concepts and tools of applied Genetic Toxicology.

    In 2008, Dr. Sobol joined Pfizer Worldwide Research and Development, where she developed as a Subject Matter Expert (SME). In 2021, she joined Merck Research Laboratories as the Director of the Genetic Toxicology Group responsible for scientific strategy, overseeing the conduct of exploratory and GLP genetic toxicology studies, and providing input at all stages of drug discovery and development.

    Over the years, Dr. Sobol has participated in various organizations and working groups, including the HESI-Genetic Toxicology Technical Committee, the Genetic Toxicology subcommittee of the Oligonucleotide Safety Working Group, the Genetic Toxicology Association, and the Environmental Mutagenesis and Genomics Society, where she served in various leadership positions. Her work includes risk management of positive genotoxicity findings, risk assessment of novel therapeutic modalities, testing strategy for mutagenic impurities (including nitrosamines), and application of new tools and concepts to address challenges in applied genetic toxicology.

    Debra Tokarz, DVM, PhD, DACVP

    Debra Tokarz, DVM, PhD, DACVP

    Senior Principal Pathologist

    Genentech, Inc.

    Dr. Debra Tokarz is a senior principal scientist and head of digital pathology analytics in Translational Safety at Genentech, Inc. She obtained her veterinary medical degree from Michigan State University and completed PhD training in Comparative Biomedical Sciences at North Carolina State University. Following residency at the University of California, Davis, she became board-certified in anatomic pathology in 2011. Over the past 10 years, Dr. Tokarz has built expertise in neuropathology and has been at the forefront of developing AI-based image analysis solutions for toxicologic pathology. She lives in Raleigh, North Carolina, where she loves to read, crochet, and take over a karaoke mic.

    Hanan Ghantous, PhD, DABT, US FDA

    Timothy McGovern, PhD, White Oak Regulatory Tox, LLC

    Natalie Holman, PhD, DABT, Eli Lilly and Company

    Buay Permpoontaweesup, ACT Staff Liaison

    Registration Fees

    Early-Bird Registration
    (Received by March 4)
    Regular Registration
    (Begins March 5)
    ACT Member $1,800 $1,900
    ACT Student or Postdoc Member $995 $1,095
    Nonmember $2,100$2,200
    Government* $1,800 $1,900
    ACT Member Group Rate**
    (3 or more from same company)
    $1,650$1,750
    ACT Member Group Rate**
    (10 or more from same company)
    $1,550$1,650
    Nonmember Group Rate**
    (3 or more from same company)
    $1,950 $2,050
    Nonmember Group Rate**
    (10 or more from same company)
    $1,850$1,950

    Fees are accessed according to the membership status at the time of purchase (there are no exceptions and there are no refunds).

    *Government Registration Policy: The government registration rate is specifically designated for federal, state, or local employees of government departments/agencies who are actively participating in the course as official government personnel. Employees of public academic institutions, nonprofit institutions, or government contractors do not qualify for the discounted government rate. To register under the government rate, individuals must use their government-affiliated email address for verification purposes. ACT may request further documentation of government employment before the registration is finalized. If you are unsure you qualify for the government rate, please email ACT Headquarters before processing your payment online.

    **Group Rate Registration: To take advantage of the group rate: Please send your completed registration forms to ACT Headquarters. You will not be able to select the group rate through the online registration. All three forms (or more) should be emailed at the same time.

    Refund Policy: $100 Processing Fee will be charged if canceled before June 11, 2026, 50% refund if canceled before July 9, 2026; After July 10, 2026, no fees will be refunded. 

    Register

    Registration Form

    Course Location

    Gaithersburg Marriott Washingtonian Center
    9751 Washingtonian Boulevard
    Gaithersburg, MD 20878

    Transportation Information

    Hotel

    Gaithersburg Marriott Washingtonian Center
    9751 Washingtonian Boulevard
    Gaithersburg, MD 20878
    Tel: 301.590.0044 | 301.590.6104

    Housing Deadline

    Please refer to the ACT Room Block to make your housing reservation. The ACT meeting rate of $209 (plus tax) is offered over the dates of April 25–30, 2027, based on availability, and reservations must be made by March 26, 2027.

    Daily continental breakfast, snack breaks, and lunch are provided as part of the registration. To disclose dietary restrictions, allergies, and/or accessibility needs please email ACT Headquarters by March 26, 2027. ACT will do its best to accommodate but cannot guarantee requests will be granted.

    • You must log in to register
      • Early bird pricing available!
      • Nonmember - $2,100
      • Full Member - $1,800
      • Associate Member - $1,800
      • Emeritus Member - $1,800
      • Government Associate Member - $1,800
      • Government Full Member - $1,800
      • Postdoctoral Researcher/Transitional Member - $995
      • Student Member - $995
      • Regular Price after 03/04/2027 11:59 PM
      • Nonmember - $2,200
      • Full Member - $1,900
      • Associate Member - $1,900
      • Emeritus Member - $1,900
      • Government Associate Member - $1,900
      • Government Full Member - $1,900
      • Postdoctoral Researcher/Transitional Member - $1,095
      • Student Member - $1,095
    • More Information
  • Contains 1 Component(s) Includes a Live In-Person Event on 04/26/2027 at 8:00 AM (EDT)

    Course will be held in Gaithersburg, Maryland, from April 26–30, 2027. More information about the schedule and registration will be available soon.

    This annual ACT course provides basic training in general toxicology. Participants obtain an overall understanding of the principles of toxicology and nonclinical safety evaluation, with a focus on pharmaceutical development. The course includes a mix of lectures with breakout group discussions of regulatory case studies and hands-on analyses of nonclinical data to give participants the opportunity to apply the concepts of toxicology in the context of drug development. The course is intended to benefit individuals working with small and large molecules from biotechnology and pharmaceutical companies, CROs, and regulatory agencies, or individuals interested in or currently practicing toxicology

    The course will be held in Gaithersburg, Maryland, from April 26–30, 2027. More information about the schedule and registration will be available soon.

    The ACT course is offered exclusively in person. Virtual or hybrid participation options are not available.

    • You must log in to register
      • Early bird pricing available!
      • Nonmember - $2,100
      • Full Member - $1,800
      • Associate Member - $1,800
      • Emeritus Member - $1,800
      • Government Associate Member - $1,800
      • Government Full Member - $1,800
      • Postdoctoral Researcher/Transitional Member - $995
      • Student Member - $995
      • Regular Price after 03/04/2027 11:59 PM
      • Nonmember - $2,200
      • Full Member - $1,900
      • Associate Member - $1,900
      • Emeritus Member - $1,900
      • Government Associate Member - $1,900
      • Government Full Member - $1,900
      • Postdoctoral Researcher/Transitional Member - $1,095
      • Student Member - $1,095
    • More Information
  • Contains 1 Component(s) Includes a Live Web Event on 12/02/2026 at 11:30 AM (EST)

    (Live Session) ACT Signature Webinar

    Hosted in Collaboration with the ACT Early Career Professional Subcommittee

    image
    image


    Toxicology offers a diverse range of career opportunities across contract research organizations (CROs), pharmaceutical and biotechnology companies, and regulatory agencies. From overseeing the conduct of nonclinical studies to interpreting safety data and guiding nonclinical development strategy, toxicology professionals play critical and interconnected roles in advancing products from discovery through regulatory submission and marketing authorization. However, for students, early-career scientists, and professionals considering a career transition, understanding the available career paths and the skills required for success can be challenging.

    This webinar will provide an overview of key roles in toxicology, with a focus on study director, study monitor, and toxicologist roles. Through real-world examples, participants will gain insight into how these functions interact throughout the study lifecycle, from designing the nonclinical safety strategy to study planning and conduct, data interpretation, reporting, and regulatory filings. The webinar will also explore common career pathways and the various opportunities for specialization and advancement across CRO and pharmaceutical industry sectors. In addition, the webinar will discuss the scientific, leadership, communication, and project management competencies that contribute to success in toxicology careers. Participants will gain a clearer understanding of potential career trajectories in toxicology and actionable strategies for achieving their professional goals.

    Pallavi McElroy, PhD

    Pallavi McElroy, PhD

    Director Global Head of Study Toxicology

    J&J Innovative Medicine

    Dr. Pallavi McElroy is a toxicologist at Johnson & Johnson with extensive experience in general toxicology, developmental and reproductive toxicology (DART), GLP study conduct, and the nonclinical safety assessment of drug candidates. Prior to joining Johnson & Johnson, she earned her PhD in Toxicology from the University of Colorado and subsequently served as a DART Study Director at Charles River Laboratories. Throughout her career, Dr. McElroy has held roles as a toxicologist, study director, study monitor, people leader, and mentor to early-career toxicologists. She is recognized as a scientific leader who supports nonclinical safety strategy and risk assessment for innovative programs spanning multiple therapeutic areas and drug modalities.

    Katie Sivak, PhD, DABT

    Katie Sivak, PhD, DABT

    Director of Toxicology

    Labcorp

    Dr. Katie Sivak is a board-certified toxicologist at Labcorp with experience in nonclinical safety assessment, regulatory toxicology, and GLP study conduct. Prior to Labcorp, Dr. Sivak earned her PhD in Microbiology, Immunology, and Virology from the University of Rochester and completed a postdoctoral fellowship in Toxicology. Throughout her career, she has served as a toxicologist, study director, study director manager, and scientific leader supporting pharmaceutical and biotechnology clients across diverse therapeutic areas and modalities. In her leadership roles, she has recruited, interviewed, hired, trained, and mentored numerous study directors. Dr. Sivak is a current member of ACT's Early Career Professional Subcommittee and serves as the Podcast Subcommittee liaison.

    • You must log in to register
      • Nonmember - Free!
      • Full Member - Free!
      • Associate Member - Free!
      • Emeritus Member - Free!
      • Government Associate Member - Free!
      • Government Full Member - Free!
      • Postdoctoral Researcher/Transitional Member - Free!
      • Student Member - Free!
    • More Information
  • Contains 53 Component(s)

    2026 AM Meeting Materials

    • You must log in to register
      • Nonmember - $1,170
      • Full Member - $870
      • Associate Member - $870
      • Emeritus Member - $870
      • Government Associate Member - $870
      • Government Full Member - $870
      • Postdoctoral Researcher/Transitional Member - $275
      • Student Member - $275
    • More Information
  • Contains 3 Component(s)

    Quantitative Structure-Activity Relationship (QSAR) approaches are integral to modern toxicology. They enable predictive hazard assessment, prioritization, and regulatory decision-making without reliance on animal testing. However, many toxicologists have little experience or hands-on familiarity with how QSAR tools work or how...

    Quantitative Structure-Activity Relationship (QSAR) approaches are integral to modern toxicology. They enable predictive hazard assessment, prioritization, and regulatory decision-making without reliance on animal testing. However, many toxicologists have little experience or hands-on familiarity with how QSAR tools work or how to interpret their results. This CE course provides a structured learning pathway from foundational QSAR principles to standardized modeling and best practices to regulatory application and finally to hands-on implementation. This course will begin by establishing foundational knowledge, including an overview of the scientific principles underlying various QSAR tools and Science Behind Structure-Activity Relationships. After the foundational instruction, the session will move to a forward-looking discussion on implementing QSAR modeling using a standardized, step-by-step workflow and regulatory expectations, with each covering a distinct, non-overlapping layer of QSAR competency. The final 90-minute segment will be a fully interactive, hands-on walkthrough of the OECD QSAR Toolbox, during which participants will practice chemical profiling, analogue selection, and the execution of a regulatory-relevant read-across prediction. In summary, this session is intended to provide both informative and practical training. Designed for scientists at all experience levels, this course emphasizes transparency, reproducibility, and real-world regulatory application. Attendees will leave with a clear understanding of QSAR principles, knowledge of best-practice modeling pipelines, insight into how regulators evaluate QSAR predictions, and practical skills to apply OECD QSAR Toolbox workflows in their own safety assessments.

    CE Course Chair: Chandrakant Patel, MSc, MBA, DABT – JRF Global
    CE Course Chair: Ricardo Scheufen Tieghi, BS – Human Chemical Company
    CE Course Speaker: Alexandre Borrel, PhD – Sciome
    CE Course Speaker: Shagun Krishna, PhD – PCRM

    • You must log in to register
      • Nonmember - $510
      • Full Member - $460
      • Associate Member - $460
      • Emeritus Member - $460
      • Government Associate Member - $460
      • Government Full Member - $460
      • Postdoctoral Researcher/Transitional Member - $285
      • Student Member - $285
    • More Information